GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Other Current Assets

Sandoz Group AG (Sandoz Group AG) Other Current Assets : $731 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Other Current Assets?

Sandoz Group AG's other current assets for the quarter that ended in Dec. 2023 was $731 Mil.

Sandoz Group AG's quarterly other current assets increased from . 20 ($0 Mil) to Dec. 2022 ($320 Mil) and increased from Dec. 2022 ($320 Mil) to Dec. 2023 ($731Mil).

Sandoz Group AG's annual other current assets increased from . 20 ($0 Mil) to Dec. 2022 ($320 Mil) increased from Dec. 2022 ($320 Mil) to Dec. 2023 ($731 Mil).


Sandoz Group AG Other Current Assets Historical Data

The historical data trend for Sandoz Group AG's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Other Current Assets Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Other Current Assets
320.00 731.00

Sandoz Group AG Quarterly Data
Dec22 Dec23
Other Current Assets 320.00 731.00

Sandoz Group AG Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Sandoz Group AG Other Current Assets Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG (Sandoz Group AG) Business Description

Traded in Other Exchanges
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research 02-14-2024